

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

BOEHRINGER INGELHEIM INTERNATIONAL GMBH,
Patent Owner.

U.S. Patent No. 8,846,695 to Dugi
Issue Date: Sept. 30, 2014
Title: Treatment for Diabetes in Patients
with Inadequate Glycemic Control
Despite Metformin Therapy Comprising a DPP-IV Inhibitor

Inter Partes Review No.: IPR2016-01564

**Petition for *Inter Partes* Review of U.S. Patent No. 8,846,695 Under
35 U.S.C. §§ 311–319 and 37 C.F.R. §§ 42.1–.80, 42.100–.123**

Mail Stop “PATENT BOARD”
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. OVERVIEW	1
III. STANDING (37 C.F.R. § 42.104(a); PROCEDURAL STATEMENTS)	4
IV. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))	5
A. Each Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))	5
B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))	5
1. Judicial Matters	5
2. Administrative Matters	5
C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), 42.10(a), and 42.10(b))	5
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a))	6
VI. THE '695 PATENT	6
A. CLAIM CONSTRUCTION	7
VII. EXPERT DECLARATION OF MAYER B. DAVIDSON, M.D.	8
VIII. PERSON OF SKILL IN THE ART ("POSA")	9
IX. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b))	10
A. The Scope and Content of the Prior Art	11
1. Metformin	11
2. DPP-IV Inhibitors	12
3. The Combination of DPP-IV Inhibitors, Specifically Linagliptin, was Known in the Art	14

4.	The Benefits of Administering DPP-IV Inhibitors with Metformin in Type II Diabetes Patients with Inadequate Glycemic Control Despite Therapy with Metformin Were Well-Known	15
B.	Ground 1: Claims 1–4 Are Unpatentable Under 35 U.S.C. § 103(a) as Obvious Over Charbonnel or Hughes in View of the '940 Publication	16
1.	Charbonnel (Ex. 1004).....	16
2.	Hughes (Ex. 1005)	18
3.	The '940 Publication (Ex. 1003).....	19
4.	Independent Claims 1 and 2.....	21
5.	Dependent Claims 3 and 4	25
C.	Ground 2: Claims 1–4 Are Unpatentable Under 35 U.S.C. § 103(a) Over the Janumet Label, Nauck, or Ahrén 2008 in View of the '940 Publication	26
1.	The '940 Publication (Ex. 1003).....	26
2.	Janumet Label (Ex. 1007).....	26
3.	Nauck (Ex. 1006).....	27
4.	Ahrén 2008 (Ex. 1022)	28
5.	Independent Claims 1 and 2.....	31
6.	Dependent Claims 3 and 4	34
D.	Objective Indicia of Nonobviousness	35
X.	CONCLUSION.....	36

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Boehringer Ingelheim Pharmaceuticals Inc., et al. v. HEC Pharm Group, et al.</i> , Civ. Action No. 3:15-cv-05982-PGS-TJB (D.N.J.)	5
<i>Cuozzo Speed Techs., LLC v. Lee</i> , 136 S.Ct. 2131 (2016).....	7
<i>Daiichi Sankyo, Ltd. v. Apotex, Inc.</i> , 501 F.3d 1254 (Fed. Cir. 2007)	9
<i>In the Matter of Mahurkar Double Lumen Hemodialysis Catheter Patent Litig.</i> , 831 F. Supp. 1354 (N.D. Ill. 1993), <i>aff'd sub nom., In re Mahurkar Double Lumen Hemodialysis Catheter Patent Litig.</i> , 71 F.3d 1573 (Fed. Cir. 1995)	9
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	9
<i>Novo Nordisk A/S v. Caraco Pharm. Labs., Ltd.</i> , 719 F.3d 1346 (Fed. Cir. 2013)	3, 4
<i>Richardson-Vicks, Inc. v. Upjohn Co.</i> , 122 F.3d 1476 (Fed. Cir. 1997)	4
<i>Sinclair & Carroll Co. v. Interchemical Corp.</i> , 325 U.S. 327 (1945).....	4
<i>Standard Oil Co. v. Am. Cyanamid Co.</i> , 774 F.2d 448 (Fed. Cir. 1985)	9
STATUTES	
35 U.S.C. § 102(b)	17, 19
35 U.S.C. § 103(a)	16

35 U.S.C. §§ 311 – 319 1

OTHER AUTHORITIES

37 C.F.R. § 42 1

37 C.F.R. § 42(a)(1) 5

37 C.F.R. § 42.6(c) 10

37 C.F.R. § 42.8(b)(1) 5

37 C.F.R. § 42.8(b)(2) 5

37 C.F.R. § 42.8(b)(3) 5

37 C.F.R. § 42.10(b) 1, 5

37 C.F.R. §42.63(e) 5

37 C.F.R. § 42.100(b) 7

37 C.F.R. § 42.103 1

37 C.F.R. § 42.104(a) 4

37 C.F.R. § 42.104(b) 10

37 C.F.R. § 42.106(a) 4

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.